Ignite Creation Date:
2025-12-24 @ 12:58 PM
Ignite Modification Date:
2026-01-17 @ 8:28 AM
Study NCT ID:
NCT02745561
Status:
UNKNOWN
Last Update Posted:
2016-04-20
First Post:
2016-04-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D004938', 'term': 'Esophageal Neoplasms'}], 'ancestors': [{'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D004935', 'term': 'Esophageal Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D043169', 'term': 'Endostatins'}, {'id': 'D000077150', 'term': 'Oxaliplatin'}, {'id': 'D011878', 'term': 'Radiotherapy'}], 'ancestors': [{'id': 'D043165', 'term': 'Angiostatic Proteins'}, {'id': 'D042501', 'term': 'Angiogenic Proteins'}, {'id': 'D036341', 'term': 'Intercellular Signaling Peptides and Proteins'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D043170', 'term': 'Collagen Type XVIII'}, {'id': 'D024041', 'term': 'Non-Fibrillar Collagens'}, {'id': 'D003094', 'term': 'Collagen'}, {'id': 'D016326', 'term': 'Extracellular Matrix Proteins'}, {'id': 'D012596', 'term': 'Scleroproteins'}, {'id': 'D001685', 'term': 'Biological Factors'}, {'id': 'D056831', 'term': 'Coordination Complexes'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D013812', 'term': 'Therapeutics'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 22}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2016-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-04', 'completionDateStruct': {'date': '2018-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2016-04-19', 'studyFirstSubmitDate': '2016-04-18', 'studyFirstSubmitQcDate': '2016-04-19', 'lastUpdatePostDateStruct': {'date': '2016-04-20', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2016-04-20', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'response rate', 'timeFrame': 'week 3-4', 'description': 'Response rate will be done after 3-4 weeks following the last radiotherapy session.'}], 'secondaryOutcomes': [{'measure': 'Acute and late toxicities assessed based on the common toxicity criteria for adverse events version 3.0 (CTCAEv3.0)', 'timeFrame': 'year 0 - year 3', 'description': 'Acute and late toxicities will be assessed based on the common toxicity criteria for adverse events version 3.0 (CTCAEv3.0).'}, {'measure': 'Progression-free survival', 'timeFrame': 'year 0 - year 3', 'description': 'Progression-free survival (PFS) will be calculated from the date of chemoradiotherapy initiation to the date of documented failure (local recurrence or metastasis occurrence) or the date of the last follow-up for those remaining.'}, {'measure': 'Overall survival', 'timeFrame': 'year 0 - year 3', 'description': 'Overall survival (OS) will be determined as the time (in months) between the first day of therapy and the last follow-up or the date of death.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Endostatin', 'Oxaliplatin', 'Esophageal Cancer', 'chemoradiotherapy'], 'conditions': ['Esophageal Cancer', 'Endostatin']}, 'referencesModule': {'references': [{'pmid': '30850562', 'type': 'DERIVED', 'citation': 'Li W, Chen P, Zhang N, Song T, Wu S. Endostatin and Oxaliplatin-Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study. Oncologist. 2019 Apr;24(4):461-e136. doi: 10.1634/theoncologist.2019-0119. Epub 2019 Mar 8.'}]}, 'descriptionModule': {'briefSummary': 'Endostatin inhibits the pro-angiogenic action of basic fibroblast growth factor and vascular endothelial growth factor in esophageal cancer.This study aims at assessing the efficacy and safety of endostatin combined with concurrent chemoradiotherapy with Oxaliplatin in esophageal cancer patients.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Cytologically or histologically confirmed esophageal carcinoma\n2. Age of 18 -80\n3. ECOG performance status: 0-1;\n4. No treatments prior to enrollment;\n5. At least one measurable lesion on CT, MRI or esophageal barium exam;\n6. Normal functions of heart, lung, liver, kidney and bone marrow Blood exams qualified for chemotherapy, which included hemoglobulin ≥9 g/dl, neutrophil ≥1.5×109/L and platelet (PLT) ≥100×109/L, creatinine ≤1.5 UNL\n7. Informed consent signed\n\nExclusion Criteria:\n\n1. Prior treatments of chemotherapy or irradiation;\n2. Poor bone marrow, liver and kidney functions, which would make chemotherapy intolerable;\n3. Contraindication for irradiation: complete obstruction of esophagus, deep esophageal ulcer, fistula to mediastinum, or haematemesis;\n4. Participating in other clinical trials;\n5. Pregnancy, breast feeding, or not adopting birth control;\n6. Clinically significant and uncontrolled major medical conditions including but not limited to: active uncontrolled infection, symptomatic congestive heart failure, Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation that would limit compliance with study requirements; any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities\n7. The subject has had another active malignancy within the past five years except for cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin;'}, 'identificationModule': {'nctId': 'NCT02745561', 'briefTitle': 'Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.', 'organization': {'class': 'OTHER', 'fullName': 'Hangzhou Cancer Hospital'}, 'officialTitle': 'A Phase II Study of Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.', 'orgStudyIdInfo': {'id': 'HangzhouCH05'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Chemoradiotherapy Arm', 'description': 'Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy. Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.', 'interventionNames': ['Drug: Endostatins', 'Drug: Oxaliplatin', 'Radiation: Radiotherapy']}], 'interventions': [{'name': 'Endostatins', 'type': 'DRUG', 'description': 'Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.', 'armGroupLabels': ['Chemoradiotherapy Arm']}, {'name': 'Oxaliplatin', 'type': 'DRUG', 'description': 'Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.', 'armGroupLabels': ['Chemoradiotherapy Arm']}, {'name': 'Radiotherapy', 'type': 'RADIATION', 'description': 'Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks.', 'armGroupLabels': ['Chemoradiotherapy Arm']}]}, 'contactsLocationsModule': {'locations': [{'zip': '310000', 'city': 'Hangzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Shixiu Wu, MD', 'role': 'CONTACT', 'email': 'wushixiu@medmail.com.cn', 'phone': '+8657186826086'}, {'name': 'Tao Song, Dr', 'role': 'CONTACT', 'email': 'songtaodhp@126.com'}], 'facility': 'Hangzhou Cancer Hospital', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}], 'centralContacts': [{'name': 'Shixiu Wu, MD', 'role': 'CONTACT', 'email': 'wushixiu@medmail.com.cn', 'phone': '+8657186826086'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hangzhou Cancer Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'MD', 'investigatorFullName': 'Shixiu Wu', 'investigatorAffiliation': 'Hangzhou Cancer Hospital'}}}}